Clinical Trial Update: Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety and dose-finding study of ADVM-043 gene therapy for Alpha-1 Antitrypsin Deficiency has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• ADVM-043

Snippet

Sponsor: Adverum Biotechnologies, Inc. | Conditions: Alpha 1-Antitrypsin Deficiency | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-08-08